Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 1,992,172 |
|
|||||
| News | (1) | ||||||
| Day High | 6.22 | Low High |
|||||
| Day Low | 5.13 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| CorMedix Inc | CRMD | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.21 | -3.87% | 5.21 | 19:33:25 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 5.50 | 5.13 | 6.22 | 5.28 | 5.42 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 13,843 | 1,992,172 | $ 5.45 | $ 10,861,570 | - | 2.57 - 7.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:48:57 | 2 | $ 5.20 | USD |
CorMedix Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 290.3M | 54.98M | - | 0 | -46.34M | -0.84 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
CorMedix News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CRMD Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 6.44 | 7.00 | 5.12 | 5.58 | 1,181,346 | -1.23 | -19.10% |
| 1 Month | 3.92 | 7.00 | 3.85 | 5.27 | 812,219 | 1.29 | 32.91% |
| 3 Months | 3.23 | 7.00 | 2.89 | 4.28 | 585,502 | 1.98 | 61.30% |
| 6 Months | 3.27 | 7.00 | 2.57 | 3.76 | 712,210 | 1.94 | 59.33% |
| 1 Year | 4.70 | 7.00 | 2.57 | 4.03 | 648,046 | 0.51 | 10.85% |
| 3 Years | 7.82 | 8.94 | 2.57 | 4.40 | 414,588 | -2.61 | -33.38% |
| 5 Years | 9.76 | 18.80 | 2.57 | 5.81 | 483,698 | -4.55 | -46.62% |
CorMedix Description
| Cormedix Inc is a biopharmaceutical company that focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It has been in-licensed to develop and commercialize Neutrolin, which is a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings such as hemodialysis, total parenteral nutrition, and oncology. The Neutrolin product is designed to target unmet medical needs. |
